Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season-Reference-Cited by-同舟云学术

Brand-Specific Enhanced Safety Surveillance of GSK’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season

Published:2019-12-28 Issue:3 Volume:43 Page:265-279
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Dos Santos Gael^ORCID,Nguyen Bach-Yen,Damaso Silvia^ORCID,Godderis Lode,Martínez-Gómez Xavier,Eckermann Tamara,Loos Hugo,Salamanca de la Cueva Ignacio,Shende Vishvesh^ORCID,Schmidt Alexander C.^ORCID,Yeakey Anne^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-019-00893-4.pdf

Reference20 articles.

1. World Health Organisation (WHO). Fact Sheets. Influenza (seasonal). http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed 1 Apr 2019.

2. European Centre for Disease Prevention and Control (ECDC). Factsheet about seasonal influenza. https://ecdc.europa.eu/en/seasonal-influenza/facts/factsheet. Accessed 1 Jul 2019.

3. Foppa IM, Cheng PY, Reynolds SB, Shay DK, Carias C, Bresee JS et al. Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14. Vaccine. 2015;33(26):3003–9. https://doi.org/10.1016/j.vaccine.2015.02.042.

4. World Health Organisation (WHO). WHO recommendations on the composition of influenza virus vaccines. https://www.who.int/influenza/vaccines/virus/recommendations/en/. Accessed 1 Jul 2019.

5. Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Hum Vaccin Immunother. 2019;15(11):2624–36. https://doi.org/10.1080/21645515.2019.1608745.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014–2022) Following the Introduction of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older;Drug Safety;2024-03-14

2. Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient‐reported outcome system for vaccine safety remote monitoring;Influenza and Other Respiratory Viruses;2023-03

3. Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons;Vaccine;2023-01

4. Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season;Infectious Diseases and Therapy;2021-12-27

5. Safety Profile of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season;Drug Safety;2021-10-25